Dravet 症候群市场规模、份额、成长分析（按发作类型、按诊断、按严重程度、按治疗、按最终用户、按分销管道、按地区）- 行业预测 2025-2032

2023 年，Dravet 症候群市场规模价值为 3.7617 亿美元，预计将从 2024 年的 4.1153 亿美元增长到 2032 年的 8.4438 亿美元，预测期内（2025-2032 年）的复合年增长率为 9.4%。

Dravet 症候群是一种罕见的慢性癫痫症，主要影响出生后第一年的婴儿，并且常常由发烧引起。这种严重的神经系统疾病由于反覆发作，给管理和护理带来了重大挑战。随着 Dravet 病情的进展，患者面临各种併发症，凸显了对专业医疗照护和对患者及其家人持续支持的必要性。该疾病的复杂性和特殊性凸显了有针对性的干预和资源的重要性，推动了市场对创新治疗和全面护理解决方案的需求。开发 Dravet 症候群治疗方法和支持系统的公司有很大机会满足这个弱势患者群体的需求。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析

Dravet 症候群市场规模（依癫痫发作类型和复合年增长率） (2025-2032)

• 市场概览
• 肌阵挛性癫痫
• 猝倒症
• 局部性癫痫
• 强直阵挛性发作
• 光敏性癫痫
• 其他的

Dravet 症候群市场规模（按诊断和复合年增长率） (2025-2032)

• 市场概览
• MRI
• 心电图
• SCN1A检测

Dravet 症候群市场规模（依严重程度及复合年增长率） （2025-2032 年）

• 市场概览
• 温和的
• 缓和
• 严格的

Dravet 症候群市场规模：依治疗方法及复合年增长率（2025-2032）

• 市场概览
• 癫痫
• 药品
• Clobazam
• 司替戊醇
• 丙戊酸钠
• 生酮饮食
• 迷走神经刺激
• 其他的

Dravet 症候群市场规模（依最终使用者和复合年增长率）(2025-2032)

• 市场概览
• 製药公司
• 医院
• 诊断
• 研究所
• 学术研究所
• 其他的

德拉维特症候群市场规模（依分销管道划分）及复合年增长率（2025-2032 年）

• 市场概览
• 直接竞标
• 医院药房
• 零售药局
• 其他的

德拉维特症候群市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• Stoke Therapeutics（USA）
• Lundbeck A/S（Denmark）
• Sanofi（France）
• Biocodex SA（France）
• Jazz Pharmaceuticals plc（Ireland）
• Ovid Therapeutics Inc.（USA）
• AbbVie Inc.（USA）
• PTC Therapeutics Inc.（USA）
• Epygenix Therapeutics Inc.（USA）
• Marinus Pharmaceuticals Inc.（USA）
• Neurocrine Biosciences Inc.（USA）
• Aquestive Therapeutics Inc.（USA）
• Eisai Co., Ltd.（Japan）
• Tevard Biosciences GmbH（Germany）
• Anavex Life Sciences Corp.（USA）
• Supernus Pharmaceuticals Inc.（USA）
• Xenon Pharmaceuticals Inc.（Canada）
• Zydus Lifesciences Ltd.（India）
• Sun Pharmaceutical Industries Ltd.（India）
• Lupin Ltd.（India）

结论和建议

Dravet Syndrome Market size was valued at USD 376.17 million in 2023 and is poised to grow from USD 411.53 million in 2024 to USD 844.38 million by 2032, growing at a CAGR of 9.4% during the forecast period (2025-2032).

Dravet syndrome, a rare and chronic form of epilepsy, primarily manifests in infants during their first year of life, often triggered by fevers. This severe neurological condition leads to recurrent seizures, creating significant challenges for management and care. As Dravet progresses, patients face various complications, highlighting the critical need for specialized medical attention and continuous support for both patients and their families. The complexity and uniqueness of this disorder underscore the importance of targeted interventions and resources, indicating a demand for innovative treatments and comprehensive care solutions in the market. Companies developing therapies and support systems for Dravet syndrome have a significant opportunity to address the needs of this vulnerable patient population.

Top-down and bottom-up approaches were used to estimate and validate the size of the Dravet Syndrome market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Dravet Syndrome Market Segments Analysis

Global Dravet Syndrome Market is segmented by Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel and region. Based on Type of seizures, the market is segmented into Myoclonic Seizures, Atonic Seizures, Partial Seizures, Tonic-Clonic Seizures, Photosensitive seizures and Others. Based on Diagnosis, the market is segmented into MRI, ECG and SCN1A testing. Based on Severity, the market is segmented into Mild, Moderate and Severe. Based on Treatment, the market is segmented into Seizure, Medication, Clobazam, Stiripentol, Sodium Valproate, Ketogenic diet, Vagus Nerve stimulation and Others. Based on End-Use, the market is segmented into Pharma companies, Hospitals, Diagnostic, Laboratories, Academic and Research Institutes and Others. Based on Distribution Channel, the market is segmented into Direct Tender, Hospital pharmacy, Retail Pharmacy and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Dravet Syndrome Market

One of the key market drivers for the Global Dravet Syndrome Market is the increasing prevalence of the disorder, which is a severe form of epileptic encephalopathy typically diagnosed in childhood. As awareness of Dravet syndrome grows among healthcare professionals and the general public, there is a rising demand for effective treatment options. The development and approval of innovative therapies, particularly targeted pharmacological agents and advanced treatment modalities such as cannabidiol-based medications, are further propelling market growth. Additionally, ongoing research into the genetic and molecular mechanisms of Dravet syndrome is expected to yield novel therapeutic approaches, enhancing treatment outcomes and fostering market expansion.

Restraints in the Dravet Syndrome Market

The Dravet Syndrome market encounters several restraints that could hinder its anticipated revenue growth. One significant challenge is the persistent societal stigma surrounding epilepsy and related seizure disorders, which leads to discrimination and misinformation in various regions around the world. This stigma often discourages individuals from pursuing treatment, as they may fear the negative perceptions associated with their condition. As a result, the reluctance to seek necessary medical care could adversely impact the market, limiting access to crucial therapies and treatments for those affected by Dravet Syndrome. Addressing these societal barriers will be vital for market progress.

Market Trends of the Dravet Syndrome Market

The Dravet syndrome market is witnessing a significant upswing, driven by recent regulatory advancements that enhance treatment options for this challenging condition. Key approvals, such as those for Stiripentol (Diacomit) and Epidiolex, have notably improved symptom management, showcasing Milestones in therapeutic interventions. The landscape is poised for further growth with the anticipated approval of ZX008 (Fintepla) from Zogenix, reflecting an increasing focus on innovative therapies that address unmet medical needs in the Dravet syndrome community. This convergence of regulatory support and innovative drug development positions the market for rapid expansion, meeting the needs of patients and caregivers alike.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Dravet Syndrome Market Size by Type of seizures & CAGR (2025-2032)

• Market Overview
• Myoclonic Seizures
• Atonic Seizures
• Partial Seizures
• Tonic-Clonic Seizures
• Photosensitive seizures
• Others

Global Dravet Syndrome Market Size by Diagnosis & CAGR (2025-2032)

• Market Overview
• MRI
• ECG
• SCN1A testing

Global Dravet Syndrome Market Size by Severity & CAGR (2025-2032)

• Market Overview
• Mild
• Moderate
• Severe

Global Dravet Syndrome Market Size by Treatment & CAGR (2025-2032)

• Market Overview
• Seizure
• Medication
• Clobazam
• Stiripentol
• Sodium Valproate
• Ketogenic diet
• Vagus Nerve stimulation
• Others

Global Dravet Syndrome Market Size by End-Use & CAGR (2025-2032)

• Market Overview
• Pharma companies
• Hospitals
• Diagnostic
• Laboratories
• Academic and Research Institutes
• Others

Global Dravet Syndrome Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Direct Tender
• Hospital pharmacy
• Retail Pharmacy
• Others

Global Dravet Syndrome Market Size & CAGR (2025-2032)

• North America (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
  • US
  • Canada
• Europe (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type of seizures, Diagnosis, Severity, Treatment, End-Use, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Stoke Therapeutics (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lundbeck A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocodex S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jazz Pharmaceuticals plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ovid Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PTC Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Epygenix Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Marinus Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Neurocrine Biosciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aquestive Therapeutics Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eisai Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tevard Biosciences GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Anavex Life Sciences Corp. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Supernus Pharmaceuticals Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Xenon Pharmaceuticals Inc. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Lifesciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations